Holen Sie sich die Stockscreener-App
9.18
6.99%
-0.69
Handel nachbörslich:
9.17
-0.010
-0.11%
Schlusskurs vom Vortag:
$9.87
Offen:
$9.84
24-Stunden-Volumen:
245.75K
Relative Volume:
0.64
Marktkapitalisierung:
$522.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.86M
KGV:
-7.65
EPS:
-1.2
Netto-Cashflow:
$-58.82M
1W Leistung:
-2.13%
1M Leistung:
-6.90%
6M Leistung:
+152.20%
1J Leistung:
+80.89%
1-Tages-Spanne:
$8.87
$9.915
1-Wochen-Bereich:
$8.23
$10.17
52-Wochen-Spanne:
$2.60
$10.31
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Vergleichen Sie DSGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
9.18 | 562.23M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Can Protara Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Can Design Therapeutics Inc. stock beat market expectations this quarter2025 Key Lessons & Intraday High Probability Alerts - ulpravda.ru
Oppenheimer Initiates Coverage of Design Therapeutics (DSGN) with Outperform Recommendation - Nasdaq
Quarterly Recap: Is Design Therapeutics Inc stock a contrarian buyJuly 2025 Setups & Community Verified Trade Signals - moha.gov.vn
What analysts say about Design Therapeutics Inc stockMarket Sentiment Shifts & Breakthrough Stock Performance - earlytimes.in
2026 world cup analysis predictions: How sustainable is Design Therapeutics Inc. stock dividend payout2026 world cup usa national team round of 16 defensive leaders build up play tactical prediction statistical analysis - ulpravda.ru
Why Design Therapeutics Inc. stock appeals to analysts2026 world cup usa national team semifinals goalkeepers counter attacking winner prediction preview - ulpravda.ru
Wall Street Zen Upgrades Design Therapeutics (NASDAQ:DSGN) to "Hold" - MarketBeat
Design Therapeutics Inc Stock Analysis and ForecastTrading Psychology Tips & Free Discover Breakout Stocks Early - earlytimes.in
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why - Defense World
Design Therapeutics Inc (NASDAQ:DSGN) Nasdaq Index Genetic Focus - Kalkine Media
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5%What's Next? - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Nasdaq Futures Neurology Programs - Kalkine Media
Risk Analysis: Is Design Therapeutics Inc stock dividend yield sustainableEarnings Recap Summary & Real-Time Price Movement Reports - moha.gov.vn
How sustainable is Design Therapeutics Inc. stock dividend payoutWatch List & Pattern Based Trade Signal System - Улправда
Investment Report: Will Ingredion Incorporated stock benefit from green energy trendsJuly 2025 Closing Moves & Detailed Earnings Play Strategies - moha.gov.vn
Design Therapeutics Shares Gain Momentum on Clinical Progress - AD HOC NEWS
➡️ Break above $200 with volume bullish continuationBreakout Stock Watch & Free Stock Trading Signal Access - Bollywood Helpline
Weekly Earnings: Is Design Therapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Community Consensus Stock Picks - Улправда
Why Design Therapeutics Inc. stock is rated strong buy2025 Price Action Summary & Technical Pattern Based Signals - Улправда
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Is Design Therapeutics Inc. stock a good choice for value investorsSwing Trade & Risk Managed Investment Signals - Улправда
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia - MSN
Design Therapeutics upgraded to Outperform from Market Perform at Leerink - MSN
Can Design Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Short Interest & Expert Curated Trade Setups - Улправда
Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design - Business Wire
Design Therapeutics Earnings Notes - Trefis
Design Therapeutics (DSGN) details 295,312 performance option shares vested - Stock Titan
BlossomHill Therapeutics Announces $84 Million Financing to - GlobeNewswire
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 5.8%Time to Sell? - MarketBeat
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $14.00 - Defense World
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why retail investors pile into Design Therapeutics Inc. stockJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress By Investing.com - Investing.com South Africa
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):